Ashley Johnson is an accomplished Associate Principal Scientist at Merck, specializing in the clinical development of long-acting injectable formulations in neurology and infectious diseases, along with leading external collaborations on dissolvable microneedles. Johnson's expertise spans across discovery and preclinical pharmaceutical sciences, demonstrating strong leadership in matrixed team environments and managing significant research operations. Notably, Johnson developed an additive manufacturing technique for microneedles during a Ph.D. program at the University of North Carolina at Chapel Hill, significantly enhancing the efficiency of transdermal drug delivery systems. Educational background includes a Ph.D. in Biomedical/Medical Engineering and a Bachelor’s Degree in Biomedical Engineering from Washington University in St. Louis.